-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma in Ewing Sarcoma Drug Details: RNAi...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cyclosam in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Cyclosam in Ewing Sarcoma Drug Details: Cyclosam is under development for the treatment of osteosarcoma, Ewing...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Racemetyrosine in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Racemetyrosine in Ewing Sarcoma Drug Details: Racemetyrosine (SM-88) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Ewing Sarcoma Drug Details: Toripalimab (Tuoyi) is a monoclonal antibody, acts as an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Ewing Sarcoma Drug Details: Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4, 3, 2-de]...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Ewing Sarcoma Drug Details: Lenvatinib mesylate (Lenvima / Kisplyx / Lenvixi) is...
-
Product Insights
Ewing Bank 910 Field, United States
Ewing Bank 910 upstream field is located in Central Planning Area, United States. The upstream field is owned by W & T Energy Vi LLC (50%); W&T Offshore Inc (50%). It is operated by W&T Offshore Inc. The project started its operations in 1998. Ewing Bank 910 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production,...
-
Product Insights
Ewing Bank 988 Field, United States
Ewing Bank 988 upstream field is located in Central Planning Area, United States. The upstream field is owned by Mobil Oil Exploration & Producing Southeast Inc (73.33%); W&T Offshore Inc (26.67%). It is operated by Mobil Oil Exploration & Producing Southeast Inc. The project started its operations in 1988. Ewing Bank 988 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as...
-
Product Insights
Ewing Bank 826 Field, United States
Ewing Bank 826 upstream field is located in Central Planning Area, United States. The upstream field is owned by Fieldwood Energy LLC. It is operated by Fieldwood Energy LLC. The project started its operations in 1989. Ewing Bank 826 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and...
-
Product Insights
Ewing Bank 305 Field, United States
Ewing Bank 305 upstream field is located in Central Planning Area, United States. The upstream field is owned by Talos Energy Offshore LLC (80%); Total E&P USA Inc (20%). It is operated by Talos Energy Offshore LLC. The project started its operations in 1986. Ewing Bank 305 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production,...
-
Product Insights
Ewing Bank 998 Field, United States
Ewing Bank 998 upstream field is located in Central Planning Area, United States. The upstream field is owned by Apache Deepwater LLC (50%); Walter Oil & Gas Corp (50%). It is operated by Walter Oil & Gas Corp. The project started its operations in 2011. Ewing Bank 998 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trabectedin in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trabectedin in Ewing Sarcoma Drug Details: Trabectedin (Yondelis) is an anti tumor agent of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elimusertib in Ewing Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Elimusertib in Ewing SarcomaDrug Details:Elimusertib (BAY-1895344) is under development for the treatment of solid tumors such...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Ewing Sarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elraglusib in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elraglusib in Ewing Sarcoma Drug Details: 9-ING41 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Ewing Sarcoma Drug Details: Palbociclib (Ibrance) is a pyridopyrimidine-derived cyclin-dependent kinase (CDK)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Ewing Sarcoma Drug Details: Abemaciclib (Verzenio / Verzenios / Yulareb) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Venetoclax in Ewing Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in Ewing Sarcoma Drug Details: Venetoclax (ABT-199, GDC-0199/RG7601, Venclexta, Venclyxto) acts as an antineoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Ewing Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Ewing Sarcoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Devimistat in Ewing Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Devimistat in Ewing SarcomaDrug Details:Devimistat (CPI-613) is under development for the treatment of Burkitt lymphoma or...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.